Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 5, 2025

A Simple Step-by-Step Protocol for Hydrophilic Interaction Liquid Chromatography (HILIC) Development

Key Takeaways

  • A rationally designed protocol for HILIC method development focuses on optimizing stationary phases and mobile phase composition for improved separation of polar compounds.
  • Key parameters such as pH and buffer concentration are adjusted to enhance reproducibility and reduce development time in HILIC methods.
SHOW MORE

This knowledge note details a simple, rationally designed protocol for HILIC method development.


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.